Pulmatrix Inc
PULM5.400USD
+0.010+0.18%
Market hours （ET）Quotes delayed by 15 min
19.72MMarket Cap
LossP/E TTM
More Details of Pulmatrix Inc Company
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Company Info
Ticker SymbolPULM
Company namePulmatrix Inc
IPO dateMar 21, 2014
CEOMr. Peter B. Ludlum
Number of employees2
Security typeOrdinary Share
Fiscal year-endMar 21
Address945 Concord Street
CityFRAMINGHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code01701
Phone18883554440
Websitehttps://www.pulmatrix.com/
Ticker SymbolPULM
IPO dateMar 21, 2014
CEOMr. Peter B. Ludlum
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
7.83K
--
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Independent Director
Independent Director
4.16K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
Independent Director
Independent Director
4.16K
--
Mr. Anand Varadan
Mr. Anand Varadan
Independent Director
Independent Director
3.32K
--
Mr. Timothy McCarthy
Mr. Timothy McCarthy
Investor Relations
Investor Relations
--
--
Mr. Peter B. Ludlum
Mr. Peter B. Ludlum
Interim Chief Executive Officer and Interim Chief Financial Officer
Interim Chief Executive Officer and Interim Chief Financial Officer
--
--
Dr. Richard Batycky, Ph.D.
Dr. Richard Batycky, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
7.83K
--
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Independent Director
Independent Director
4.16K
--
Dr. Christopher H. (Chris) Cabell, M.D.
Dr. Christopher H. (Chris) Cabell, M.D.
Independent Director
Independent Director
4.16K
--
Mr. Anand Varadan
Mr. Anand Varadan
Independent Director
Independent Director
3.32K
--
Mr. Timothy McCarthy
Mr. Timothy McCarthy
Investor Relations
Investor Relations
--
--
Mr. Peter B. Ludlum
Mr. Peter B. Ludlum
Interim Chief Executive Officer and Interim Chief Financial Officer
Interim Chief Executive Officer and Interim Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, May 29
Updated: Thu, May 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Renaissance Technologies LLC
2.98%
BlackRock Institutional Trust Company, N.A.
1.50%
SBI Securities Co., Ltd.
1.43%
The Vanguard Group, Inc.
1.16%
Geode Capital Management, L.L.C.
1.11%
Other
91.81%
Shareholders
Shareholders
Proportion
Renaissance Technologies LLC
2.98%
BlackRock Institutional Trust Company, N.A.
1.50%
SBI Securities Co., Ltd.
1.43%
The Vanguard Group, Inc.
1.16%
Geode Capital Management, L.L.C.
1.11%
Other
91.81%
Shareholder Types
Shareholders
Proportion
Hedge Fund
3.00%
Investment Advisor/Hedge Fund
2.88%
Investment Advisor
1.53%
Research Firm
1.43%
Individual Investor
0.66%
Other
90.49%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
32
347.44K
9.51%
-94.22K
2025Q1
34
346.08K
9.48%
-117.47K
2024Q4
30
329.25K
9.01%
-61.75K
2024Q3
31
276.56K
7.57%
-108.94K
2024Q2
31
263.58K
7.22%
-1.04M
2024Q1
33
261.48K
7.16%
-1.04M
2023Q4
39
316.17K
8.66%
-1.16M
2023Q3
44
516.38K
14.50%
-1.18M
2023Q2
48
580.98K
16.42%
-1.18M
2023Q1
54
668.56K
18.82%
-1.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Renaissance Technologies LLC
108.92K
2.98%
-200.00
-0.18%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
54.90K
1.5%
--
--
Mar 31, 2025
SBI Securities Co., Ltd.
52.36K
1.43%
-13.83K
-20.90%
Mar 31, 2025
The Vanguard Group, Inc.
42.40K
1.16%
+7.32K
+20.87%
Mar 31, 2025
Geode Capital Management, L.L.C.
40.37K
1.11%
+3.50K
+9.48%
Mar 31, 2025
State Street Global Advisors (US)
13.95K
0.38%
--
--
Mar 31, 2025
Higgins (Michael J)
7.83K
0.21%
--
--
May 01, 2025
Dimensional Fund Advisors, L.P.
6.25K
0.17%
+1.36K
+27.72%
May 31, 2025
Batycky (Richard P. Ph.D.)
4.69K
0.13%
--
--
May 01, 2025
Bazemore (Todd M)
4.16K
0.11%
--
--
May 01, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Date
Type
Ratio
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
Feb 25, 2022
Merger
20<1
